开云app官网登录入口网页版-官方正版

#帕妥珠单抗#

3篇内容 | 1485人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2205451, encodeId=3580220545173, content=<a href='/topic/show?id=cbef6022e4c' target=_blank style='color:#2F92EE;'>#曲妥珠单抗#</a> <a href='/topic/show?id=e56a48488ce' target=_blank style='color:#2F92EE;'>#帕妥珠单抗#</a> <a href='/topic/show?id=a9ef83546d6' target=_blank style='color:#2F92EE;'>#胆道癌#</a>, objectTitle=JCO：TAPUR研究：帕妥珠单抗+曲妥珠单抗后线治疗HER2/3变异胆道癌的DCR达40%, objectType=article, longId=826433, objectId=9e36826433ba, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240518/1716043803561_5579292.png, objectUrl=/article/show_article.do?id=9e36826433ba, replyNumber=0, likeNumber=0, createdTime=2024-05-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9e36826433ba, moduleTitle=JCO：TAPUR研究：帕妥珠单抗+曲妥珠单抗后线治疗HER2/3变异胆道癌的DCR达40%, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9e36826433ba)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2198060, encodeId=7db621980604a, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=cbef6022e4c' target=_blank style='color:#2F92EE;'>#曲妥珠单抗#</a> <a href='/topic/show?id=e56a48488ce' target=_blank style='color:#2F92EE;'>#帕妥珠单抗#</a>, objectTitle=曲妥珠单抗联合帕妥珠单抗治疗HER2扩增晚期结直肠癌有效，且治疗前再次分子检测有必要, objectType=article, longId=821193, objectId=51b582119360, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-a-medical-recipe-P8LEKCP.jpg, objectUrl=/article/show_article.do?id=51b582119360, replyNumber=0, likeNumber=85, createdTime=2024-04-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=51b582119360, moduleTitle=曲妥珠单抗联合帕妥珠单抗治疗HER2扩增晚期结直肠癌有效，且治疗前再次分子检测有必要, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=51b582119360)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2192946, encodeId=d26f2192946ad, content=<a href='/topic/show?id=e56a48488ce' target=_blank style='color:#2F92EE;'>#帕妥珠单抗#</a> <a href='/topic/show?id=78aa999190f' target=_blank style='color:#2F92EE;'>#靶向治疗#</a> <a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, objectTitle=Nat Commun：PEONY临床试验长期结果：双HER2靶向治疗对HER2阳性早期乳腺癌患者具有临床益处, objectType=article, longId=816993, objectId=3d0181699352, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240313/1710305219776_6145188.jpg, objectUrl=/article/show_article.do?id=3d0181699352, replyNumber=0, likeNumber=84, createdTime=2024-03-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3d0181699352, moduleTitle=Nat Commun：PEONY临床试验长期结果：双HER2靶向治疗对HER2阳性早期乳腺癌患者具有临床益处, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3d0181699352)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2130150, encodeId=63d8213015084, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>联合化疗联合或不联合<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>治疗持续性、复发性或转移性<a href='/topic/show?id=146246308d1' target=_blank style='color:#2F92EE;'>#宫颈癌#</a><a href='/topic/show?id=e56a48488ce' target=_blank style='color:#2F92EE;'>#帕妥珠单抗#</a>, objectTitle=2023 NICE 技术鉴定指导意见：派姆单抗联合化疗联合或不联合贝伐单抗治疗持续性、复发性或转移性宫颈癌[TA885], objectType=guider, longId=23848, objectId=c7d921c003120978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=c7d921c003120978, replyNumber=0, likeNumber=123, createdTime=2023-05-05, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c7d921c003120978, moduleTitle=2023 NICE 技术鉴定指导意见：派姆单抗联合化疗联合或不联合贝伐单抗治疗持续性、复发性或转移性宫颈癌[TA885], moduleType=guider, hrefUrl=//www.sandwebs.com/guideline/show_article.do?id=c7d921c003120978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1233075, encodeId=b5e612330e57c, content=<a href='/topic/show?id=bde99e900e0' target=_blank style='color:#2F92EE;'>#阿特珠单抗#</a>、<a href='/topic/show?id=f38743453f7' target=_blank style='color:#2F92EE;'>#多西他赛#</a>、<a href='/topic/show?id=cbef6022e4c' target=_blank style='color:#2F92EE;'>#曲妥珠单抗#</a>和<a href='/topic/show?id=e56a48488ce' target=_blank style='color:#2F92EE;'>#帕妥珠单抗#</a>新辅助治疗ERBB2阳性早期<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>的效果, objectTitle=JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果, objectType=article, longId=732001, objectId=e4e7e32001b1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220710/1657426515822_2110107.JPG, objectUrl=/article/show_article.do?id=e4e7e32001b1, replyNumber=0, likeNumber=173, createdTime=2022-07-17, rootId=0, userName=清风徐来2022, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4e7e32001b1, moduleTitle=JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e4e7e32001b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1004065, encodeId=4bd71004065a7, content=<a href='/topic/show?id=cbef6022e4c' target=_blank style='color:#2F92EE;'>#曲妥珠单抗#</a>曾经的王者！<a href='/topic/show?id=e56a48488ce' target=_blank style='color:#2F92EE;'>#帕妥珠单抗#</a>, objectTitle=JCO：帕妥珠单抗联合高剂量曲妥珠单抗有望改善伴有脑转移的HER2阳性乳腺癌患者的预后, objectType=article, longId=211004, objectId=c2ae2110047c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/multiple-sclerosis-s13-mri-brain-and-spinal-cord.jpg, objectUrl=/article/show_article.do?id=c2ae2110047c, replyNumber=0, likeNumber=184, createdTime=2021-07-30, rootId=0, userName=小小医者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2ae2110047c, moduleTitle=JCO：帕妥珠单抗联合高剂量曲妥珠单抗有望改善伴有脑转移的HER2阳性乳腺癌患者的预后, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c2ae2110047c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

帕妥珠单抗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#曲妥珠单抗# #帕妥珠单抗# #胆道癌#

JCO：TAPUR研究：帕妥珠单抗+曲妥珠单抗后线治疗HER2/3变异胆道癌的DCR达40%

2024-05-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#结直肠癌# #曲妥珠单抗# #帕妥珠单抗#

曲妥珠单抗联合帕妥珠单抗治疗HER2扩增晚期结直肠癌有效，且治疗前再次分子检测有必要

2024-04-11发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#帕妥珠单抗# #靶向治疗# #乳腺癌#

Nat Commun：PEONY临床试验长期结果：双HER2靶向治疗对HER2阳性早期乳腺癌患者具有临床益处

2024-03-13发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

#派姆单抗#联合化疗联合或不联合#贝伐单抗#治疗持续性、复发性或转移性#宫颈癌##帕妥珠单抗#

2023 NICE 技术鉴定指导意见：派姆单抗联合化疗联合或不联合贝伐单抗治疗持续性、复发性或转移性宫颈癌[TA885]

2023-05-05发表于上海

清风徐来2022 (审核中...)

前往app查看评论内容

#阿特珠单抗#、#多西他赛#、#曲妥珠单抗#和#帕妥珠单抗#新辅助治疗ERBB2阳性早期#乳腺癌#的效果

JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果

2022-07-17

小小医者 (审核中...)

前往app查看评论内容

#曲妥珠单抗#曾经的王者！#帕妥珠单抗#

JCO：帕妥珠单抗联合高剂量曲妥珠单抗有望改善伴有脑转移的HER2阳性乳腺癌患者的预后

2021-07-30

科室
- - 订阅+
  - 更多科室
工具
服务